The Adherence Patterns Shaping Oncology Outcomes

Oncology adherence may seem unpredictable, but access to patient behavior data reveals clear and consistent patterns. Medisafe's analysis of millions of managed doses,  12+ years of data, and over 130 behavioral signals per patient uncovered the factors most strongly influencing treatment persistence.

The results indicate that long-term persistence reflects a complex interplay of behavioral, environmental, and treatment-related factors. Together, these insights provide a deeper understanding of the variables shaping oncology adherence and where opportunities for intervention may exist.

Predictable Behavioral Drivers of Oncology Adherence

Across oncology patient populations, Medisafe identified four behavioral trends that influence persistence:

• The U.S. ranked among the lowest reported oncology adherence rates compared to several developed nations
• Medication dosing time plays a measurable role in adherence consistency, with certain times of day better aligning with patients' established routines and behaviors.
• Dosage patterns differ across cancer types, suggesting that disease characteristics can influence long-term engagement with therapy.
• Treatment complexity decreases adherence risk, with persistence increasing as patients manage complex dosing requirements.

These findings demonstrate that adherence challenges often emerge long before a patient abandons therapy entirely.

The Gaps in Traditional Oncology Patient Support Programs

The findings suggest that oncology adherence follows identifiable patterns, but many patient support programs are not designed to respond to them. While factors such as dosing schedules, treatment complexity, and patient routines influence engagement, support is often delivered through static reminders and standardized outreach.

A patient receiving treatment for thyroid cancer may face different adherence challenges than someone managing breast or lung cancer. Likewise, a patient taking medication during a well-established morning routine requires different support than someone whose dosing schedule is more difficult to maintain consistently.

Without a deeper understanding of these evolving patient needs, support programs fail to recognize emerging adherence risks and miss opportunities to deliver meaningful interventions when they are needed most.

Behavioral Intelligence for Better Adherence and Support

Medisafe's engagement engine is built on over a decade of real-world patient behavior data, collected across millions of patient journeys. Medisafe helps pharmaceutical organizations identify adherence risk before therapy abandonment.

By analyzing therapy-specific adherence behaviors and early risk signals, Medisafe helps pharmaceutical organizations better understand when and how to intervene, enabling more tailored support and more effective patient engagement throughout the cancer treatment journey.

The result is a more proactive approach to patient support designed to strengthen adherence, improve persistence, and maximize the value of oncology therapies.

New Insights Into Oncology Patient Behavior

Medisafe's latest oncology adherence analysis examines how geography, cancer type, and treatment complexity influence long-term treatment engagement and persistence.

The findings offer pharmaceutical teams a deeper understanding of the behavioral drivers behind adherence and actionable opportunities to strengthen patient support programs.